TP53 and metabolic dysfunction-associated steatohepatitis: The liver p53 and p66Shc signaling pathways are enhanced in a mouse model of NASH, and p53 deletion can inhibit the enhanced p66Shc signaling, reduce hepatic lipid peroxidation and the number of apoptotic hepatocytes, and improve the progression of nutritional steatohepatitis.